Scott M Norberg
Overview
Explore the profile of Scott M Norberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1098
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robbins Y, Lassoued W, Bai K, Huynh A, Norberg S, Allen C
Laryngoscope
. 2025 Mar;
PMID: 40078078
Objectives: Prior studies have reported low or absent major HLA class I expression on respiratory papilloma cells, conflicting with the recent clinical success of immunotherapy designed to activate HPV-specific T...
2.
Norberg S, Valdez J, Napier S, Kenyon M, Ferraro E, Wheatley M, et al.
Lancet Respir Med
. 2025 Jan;
PMID: 39855244
Background: Recurrent respiratory papillomatosis (RRP) is a rare debilitating condition caused by chronic infection with human papillomavirus (HPV) type 6 or 11. Papillomas develop in the aerodigestive tract, leading to...
3.
Zhang L, Norberg S, Karimipour F, Davies J, Kuznetsov A, Lassoued W, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39557544
Background: Adoptive T-cell therapy has demonstrated clinical activity in B-cell malignancies, offering hope for its application to a broad spectrum of cancers. However, a significant portion of patients with solid...
4.
Quantification and Functional Studies of Neutrophilic Cells Identifies Distinct Papilloma Phenotypes
Bai K, Clavijo P, Robbins Y, Norberg S, Allen C
Laryngoscope
. 2024 Mar;
134(7):3238-3244.
PMID: 38436434
Objectives: To characterize the distribution of immune cell subsets within laryngeal papillomas and to study the function of potentially immunosuppressive neutrophilic and regulatory T cells (Tregs). Methods: Fresh clinical papilloma...
5.
Norberg S, Bai K, Sievers C, Robbins Y, Friedman J, Yang X, et al.
Sci Transl Med
. 2023 Oct;
15(719):eadj0740.
PMID: 37878675
Recurrent respiratory papillomatosis (RRP) is a rare, debilitating neoplastic disorder caused by chronic infection with human papillomavirus (HPV) type 6 or 11 and characterized by growth of papillomas in the...
6.
Ishii K, Davies J, Sinkoe A, Nguyen K, Norberg S, McIntosh C, et al.
Sci Adv
. 2023 Jul;
9(30):eadg9845.
PMID: 37494434
T cell receptor (TCR)-engineered T cell therapy using high-affinity TCRs is a promising treatment modality for cancer. Discovery of high-affinity TCRs especially against self-antigens can require approaches that circumvent central...
7.
Cornetta K, Yao J, House K, Duffy L, Adusumilli P, Beyer R, et al.
Mol Ther
. 2022 Dec;
31(3):801-809.
PMID: 36518078
The clinical impact of any therapy requires the product be safe and effective. Gammaretroviral vectors pose several unique risks, including inadvertent exposure to replication competent retrovirus (RCR) that can arise...
8.
Norberg S, Hinrichs C
Cancer Cell
. 2022 Nov;
41(1):58-69.
PMID: 36400016
Engineered T cell therapy has shown remarkable efficacy in hematologic malignancies and has the potential for application to common epithelial cancers. Diverse T cell therapy strategies including adoptive transfer of...
9.
Shao L, Shi R, Zhao Y, Liu H, Lu A, Ma J, et al.
J Transl Med
. 2022 Nov;
20(1):514.
PMID: 36348415
Background: Clinical CAR T-cell therapy using integrating vector systems represents a promising approach for the treatment of hematological malignancies. Lentiviral and γ-retroviral vectors are the most commonly used vectors in...
10.
Bai K, Norberg S, Sievers C, Meyer T, Friedman J, Hinrichs C, et al.
Head Neck
. 2022 Jul;
44(10):E31-E37.
PMID: 35815785
Background: Immune checkpoint blockade can provide clinical benefit for patients with advanced cancer. Here, we report durable disease control over many years following PD-L1 blockade through induction of a viral...